Media stories about Allscripts Healthcare Solutions (NASDAQ:MDRX) have trended somewhat positive this week, according to Accern Sentiment. Accern identifies negative and positive media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Allscripts Healthcare Solutions earned a daily sentiment score of 0.19 on Accern’s scale. Accern also gave news articles about the software maker an impact score of 46.8078426008353 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
These are some of the news articles that may have impacted Accern Sentiment’s scoring:
- Allscripts Healthcare Solutions, Inc. (MDRX) Describing Technical Facts through volume and Volatility Indicators – Investing News Update (investingbizz.com)
- Intriguing Stocks: Allscripts Healthcare Solutions, Inc., (NASDAQ: MDRX), Tapestry, Inc., (NYSE: TPR); – TNN (tradingnewsnow.com)
- Traders Alert on Allscripts Healthcare Solutions, Inc. (MDRX) – Wall Street Morning (wallstreetmorning.com)
- Allscripts Healthcare Solutions, Inc. (MDRX) finishes with -1.35% while stock price is worth at $13.17 – Nasdaq Fortune (press release) (nasdaqfortune.com)
- Why Is Allscripts (MDRX) Down 11.3% Since its Last Earnings Report? – Nasdaq (nasdaq.com)
Several equities research analysts have recently commented on MDRX shares. Cantor Fitzgerald reaffirmed a “buy” rating and set a $17.00 price target on shares of Allscripts Healthcare Solutions in a research report on Monday, January 8th. Maxim Group reaffirmed a “buy” rating and set a $20.00 price target on shares of Allscripts Healthcare Solutions in a research report on Tuesday, January 9th. BidaskClub lowered shares of Allscripts Healthcare Solutions from a “buy” rating to a “hold” rating in a research report on Friday, January 19th. Royal Bank of Canada set a $19.00 price target on shares of Allscripts Healthcare Solutions and gave the company a “buy” rating in a research report on Thursday, January 11th. Finally, Zacks Investment Research lowered shares of Allscripts Healthcare Solutions from a “hold” rating to a “sell” rating in a research report on Friday, January 12th. One analyst has rated the stock with a sell rating, six have assigned a hold rating and twelve have given a buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $16.09.
MDRX stock opened at $12.69 on Wednesday. The stock has a market capitalization of $2,381.80, a P/E ratio of -11.64, a P/E/G ratio of 1.70 and a beta of 1.20. The company has a debt-to-equity ratio of 1.33, a quick ratio of 0.97 and a current ratio of 0.97. Allscripts Healthcare Solutions has a 52 week low of $11.25 and a 52 week high of $16.13.
Allscripts Healthcare Solutions (NASDAQ:MDRX) last announced its quarterly earnings data on Thursday, February 15th. The software maker reported $0.18 earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of $0.18. Allscripts Healthcare Solutions had a positive return on equity of 7.36% and a negative net margin of 10.88%. The company had revenue of $547.00 million during the quarter, compared to the consensus estimate of $524.05 million. During the same period in the previous year, the company posted $0.14 EPS. The firm’s revenue was up 27.5% on a year-over-year basis. research analysts predict that Allscripts Healthcare Solutions will post 0.56 earnings per share for the current year.
In other Allscripts Healthcare Solutions news, EVP Brian Farley sold 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, March 14th. The stock was sold at an average price of $13.73, for a total value of $68,650.00. Following the completion of the transaction, the executive vice president now directly owns 240,672 shares in the company, valued at approximately $3,304,426.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, President Richard J. Poulton sold 15,000 shares of the company’s stock in a transaction that occurred on Thursday, March 15th. The stock was sold at an average price of $13.53, for a total value of $202,950.00. Following the completion of the transaction, the president now owns 505,920 shares of the company’s stock, valued at $6,845,097.60. The disclosure for this sale can be found here. Corporate insiders own 0.91% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Somewhat Positive News Coverage Somewhat Unlikely to Impact Allscripts Healthcare Solutions (MDRX) Stock Price” was reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this article on another domain, it was stolen and reposted in violation of United States and international trademark & copyright laws. The correct version of this article can be read at https://ledgergazette.com/2018/03/21/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-allscripts-healthcare-solutions-mdrx-stock-price.html.
Allscripts Healthcare Solutions Company Profile
Allscripts Healthcare Solutions, Inc (Allscripts) delivers information technology (IT) solutions and services to help healthcare organizations. The Company operates through three segments: Clinical and Financial Solutions, Population Health, and Netsmart. The Clinical and Financial Solutions segment includes the sale of integrated clinical software applications and financial and information solutions.
Receive News & Ratings for Allscripts Healthcare Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allscripts Healthcare Solutions and related companies with MarketBeat.com's FREE daily email newsletter.